Publications by authors named "N Van As"
Due to the increase in data rate in mobile communication and the widespread use of mobile internet, electromagnetic communication systems are increasing daily. This situation causes increases in the use of more mobile communication devices and environmental non-ionizing Electromagnetic Field (EMF) levels. The rise of bee deaths and colony losses in beekeeping parallel to the increase of the EMF sources cause the concept of "electromagnetic pollution" to be considered among the reasons.
View Article and Find Full Text PDFObjectives: To quantify the stage-shift with prostate-specific membrane antigen (PSMA) PET/CT imaging in metastatic prostate cancer and explore treatment implications.
Methods: Single-centre, retrospective analysis of patients with newly diagnosed [F]PSMA-1007 or [Ga]Ga-PSMA-11 PET/CT-detected metastatic prostate cancer who had baseline bone scintigraphy between January 2015 and May 2021. Patients were subclassified into oligometastatic and polymetastatic disease utilizing the STAMPEDE2 trial (ISRCTN66357938/NCT06320067) definition.
Article Synopsis
- A study investigated whether stereotactic body radiotherapy (SBRT) is just as effective as standard radiotherapy for treating localized prostate cancer in terms of treatment failure rates.
- The trial involved 874 men with early-stage prostate cancer, comparing SBRT (36.25 Gy in 5 sessions) to conventional radiotherapy (78 Gy in 39 sessions or 62 Gy in 20 sessions) over several weeks, focusing on the chance of being free from cancer progression after 5 years.
- Results showed that SBRT was noninferior to standard treatment, with similar success rates in preventing cancer failure (95.8% for SBRT vs. 94.6% for control) but higher rates of genitour
Background And Objective: Randomised data on patient-reported outcomes (PROs) for stereotactic body radiotherapy (SBRT) and prostatectomy in localised prostate cancer are lacking. PACE-A compared patient-reported health-related quality of life after SBRT with that after prostatectomy.
Methods: PACE is a phase 3 open-label, randomised controlled trial.